Aparito was founded in 2014 by Dr.Elin Haf Davies.
Early in her career as a paediatric nurse, Elin experienced first hand the often redundant, time consuming, and even painful tests that were carried out in order to monitor patients taking part in clinical trials. She also recognised the challenges involved in bringing new and innovative drugs to market in the shortest possible time to improve the lives of people suffering from rare diseases.
With 20 years of clinical, research and regulatory experience under her belt, Elin was determined to help people with rare diseases get access to treatments that could genuinely improve the quality of their lives. Her response was to design a patient-centric, remote monitoring solution with the healthcare provider in mind to support the development of new therapies.
Since inception, Aparito’s vision has attracted a world-class group of regulatory experts, clinicians and technologists to build a unique team, dedicated to improving the lives of people with rare diseases.
Enhancing clinical trials with technology
We have built a platform that reduces the burden of collecting patient data for both patients and physicians alike.
Using our Atom5 system, data is collected via a mobile application and wearable devices. Trials can be conducted any time, anywhere in the world, broadening the scope of potential research.
Our platform and reporting system ensures data is consistent, continuous and cost-effective giving researchers a more rounded view of patient symptoms and wellbeing.
Real-time data is efficiently delivered to create a more accurate and meaningful picture of how a treatment works, or a disease progresses. Additionally, by offering wearables that are smaller and more attractive for paediatric patients to wear, we can enhance data capture from those younger patients who have traditionally been more difficult to assess.
Our unique multi-disciplinary team comprises clinicians, global regulatory experts, clinical trials specialists and technologists.
Dr Elin Haf Davies
Experienced clinician with a track record of more than 22+years within rare disease and regulatory (European Medicines Agency). Outside of work, Elin Haf is an adventurer who has rowed the Atlantic and Indian Ocean and competes at an international level in yacht races.
Daniel has first-hand experience of caring for a family member with a rare disease after his daughter was diagnosed with Tay-Sachs in 2011. As the founder of the rare disease charity The Cure & Action for Tay-Sachs (CATS) Foundation, he is fully aware of the challenges that many families face when taking part in clinical trials whilst also juggling their day to day life.
Dr Ian Radford
With 30+ years in software engineering and AI, Ian has a plethora of experience within pharmaceuticals, finance and digital technology. After a PhD in Artificial Intelligence and several years of academic research, giving him a solid understanding of the scientific process, Ian brings a focus on innovation alongside quality engineering.
10+ years experience in pediatric global clinical research at the European Medicines Agency working with the FDA and acting as an expert for the International Conference of Harmonisation. Co-authored globally recognised EMA extrapolation framework.
Liam has spent his career scaling clinical trial organisations, he has led all the major groups for clinical trials including; Project Management, Clinical Operations, Patient Recruitment, Data, Medical and Scientific and Laboratory services. His previous position was part of Executive team for a CRO/Biotech company which he took public on LSE:AIM.